GLP1R and stroke disorder: There was no heterogeneity in these six included studies in their assessment of the effect of GLP-1 receptor agonists on the risk of death from cardiovascular causes and fatal or non-fatal stroke; however, there was mild heterogeneity regarding the risk of fatal or non-fatal myocardial infarction in the included studies, and the reasons may be the specific medicine molecule and GLP-1 receptor agonist dose tested, differences in the randomized patients (such as medical history and baseline characteristics), duration of follow-up years and adherence to treatment.